Video

Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.

Transcript:

Saad Z. Usmani, MD: The combination of daratumumab with venetoclax and dexamethasone has been evaluated and reported on previously, primarily focusing on translocation (11;14) relapsed/refractory multiple myeloma. The initial dose-escalation study has previously been presented showing that this combination is very active for patients with translocation (11;14). At ASH [American Society of Hematology annual meeting] this year [2021], my colleague Jonathan Kaufman, [MD,] from Emory University had reported on the third part, which was a randomized phase 2 study part comparing venetoclax, daratumumab, dexamethasone to daratumumab, bortezomib, dexamethasone in patients with translocation (11;14). What he showed was a clear benefit in favor of the venetoclax, daratumumab, dexamethasone combination.

Now, this is a small randomized phase 2 study with a highly selected translocation (11;14) population. The safety profile looked tolerable. The responses were very high in favor of the venetoclax, daratumumab, dexamethasone combination. At the dose of 400 mg, I think the response rates were somewhere in the mid-70% range, whereas with the 800 mg dose of venetoclax, the responses were almost 100%. I’m excited about these data. I think we just need to see long-term follow-up to see if these responses are translating into PFS [progression-free survival] benefit for this patient population.

Transcript edited for clarity.

Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD